Major Cos. Urge Justices To Hear Generics Discovery Row

Law360 (March 17, 2020, 6:31 PM EDT) -- A dozen companies including Microsoft Corp., GlaxoSmithKline PLC and 3M Co. have urged the U.S. Supreme Court to take up a challenge from drugmakers to the discovery process in multidistrict litigation over an alleged industry-wide generic drug price-fixing conspiracy.

The companies filed an amicus brief Monday supporting a petition from generic heavyweights — including Actavis, Amneal, Impax, Sandoz and Teva — that are looking to halt what they call an “inverted discovery procedure” in the wide-ranging MDL.

The brief argued that the order is the most recent and “most distressing” example of a growing trend towards discovery processes that force parties to turn...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!